Palavras-chave
Estadiamento de Neoplasias
Neoplasias Urogenitais
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Caracterizar o perfil epidemiológico, o estadiamento e os padrões terapêuticos das principais neoplasias ginecológicas, geniturinárias e anal registrados em estabelecimentos hospitalares em Goiás entre 2019 e 2024.Métodos: Estudo ecológico, descritivo e retrospectivo, utilizando dados do TABNET/DATASUS de Goiás (2019–2024). Foram analisadas características demográficas, estadiamento clínico e modalidades terapêuticas das principais neoplasias ginecológicas e geniturinárias, por meio de análise descritiva das frequências absolutas e relativas. Resultados: Foram identificados 10.001 casos de neoplasias, com predomínio do câncer de próstata, seguido pelos cânceres do colo do útero, ovário e corpo do útero. Observou-se elevada frequência de diagnósticos em estágios avançados na maioria das neoplasias analisadas. Os cânceres de próstata, pênis, ânus, vagina e vulva ocorreram predominantemente em pacientes mais idosos, enquanto o câncer de testículo acometeu principalmente adultos jovens. A cirurgia foi a principal modalidade terapêutica, enquanto a quimioterapia predominou nos cânceres de próstata, colo do útero e ânus. Conclusão: As principais neoplasias ginecológicas, geniturinárias e analem Goiás apresentaram elevada frequência de diagnóstico em estágios avançados e diferenças no perfil etário e terapêutico. Esses achados reforçam a importância de estratégias de prevenção, rastreamento e diagnóstico precoce, contribuindo para o aprimoramento das políticas públicas voltadas ao controle dessas neoplasias.
Referências
ALLEMANI C, MATSUDA T, DI CARLO V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet. 2018;391(10125):1023-1075.
ARMSTRONG DK, ALVAREZ RD, BAKKUM-GAMEZ JN, et al. Ovarian cancer, version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 2021; 19(2): 191-226.
ARNOLD M, MORGAN E, RUMGAY H, et al. Current and future burden of incident cancer in Europe: a population-based study. The Lancet Regional Health – Europe, 2022; 22: 100510.
BHATLA N, AOKI D, SHARMA DN, SANKARANARAYANAN R. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143(Suppl 2):22-36.
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
CHENG L, ALBERS P, BERNEY DM, et al. Testicular cancer. Nat RevDis Primers. 2018;4:29.
COLOMBO N, LEDERMANN JA, et al. Ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833-848.
CONCIN N, MATIAS-GUIU X, VERGOTE I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39.
CROSBIE EJ, KITSON SJ, MCALPINE JN, et al. Endometrial cancer. Nat RevDis Primers. 2022;8(1):22.
DE MAGALHÃES JP. How ageing processes influence cancer. Nat Rev Cancer. 2013;13(5):357-365.
EUROPEAN ASSOCIATION OF UROLOGY. EAU Guidelines on Penile Cancer. Arnhem: EuropeanAssociationofUrology; 2025.
EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY. ESMO Clinical Practice Guideline for Cervical Cancer. Lugano: ESMO; 2023.
GIONA S. The epidemiology of prostate cancer. In: Prostate Cancer. Brisbane: Exon Publications; 2021.
GIRDA E, RANDALL LM, CHINO F, et al. Cervical cancer treatment update: a Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol. 2023;179:115-122.
HAKENBERG OW, COMPÉRAT EM, MINHAS S, et al. EAU Guidelines on Penile Cancer: 2023 update. Eur Urol. 2023.
HAMDY FC, DONOVAN JL, LANE JA, et al. 15-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2023;388(8):718-732.
HUANG Y, et al. Incidence distributions, risk factors and trends of vaginal cancer: population-based study. BMC Cancer. 2024;24(1):456.
INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA. Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2022.
KNAUL FM, ARREOLA-ORNELAS H, et al. Closing the cancer divide: an equity imperative. The Lancet, 2022; 400(10357): 1198-1226.
LHEUREUX S, BRAUNSTEIN M, OZA AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304.
MOTTET N, et al. EAU guidelines on prostate cancer. Arnhem: European Association of Urology; 2025.
NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN Clinical Practice Guidelines in Oncology. Plymouth Meeting (PA): NCCN; 2025.
NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma. Plymouth Meeting (PA): NCCN; 2025.
NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN Clinical Practice Guidelines in Oncology: Vulvar Cancer. Plymouth Meeting (PA): NCCN; 2025.
NEAL RD, THARMANATHAN P, FRANCE B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. British Journal of Cancer, 2015; 112(Suppl 1): S92-S107.
OLIVEIRA NPD, et al. Social inequalities in the diagnosis of cervical cancer in advanced stages in Brazil. CienSaude Colet. 2024;29(6):e03872023.
PERNAR CH, EBOT EM, WILSON KM, et al. The epidemiology of prostate cancer. Cold Spring HarbPerspect Med. 2018;8(12):a030361.
RAO S, GUREN MG, KHAN K, et al. Anal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(9):1087-1100.
RAWLA P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63-89.
RYAN NAJ, MCMAHON RF, et al. Risk factors for ovarian cancer: an umbrella review of the literature. Cancers (Basel). 2022;14(11):2708.
SEKHOACHA M, RIET K, MOTLOUNG P, et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730.
SILVA M, MARQUES R, COSTA L. Câncer de colo de útero: barreiras preventivas no século 21. Cad Med. 2020;3(1):58-69.
SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
TATEO V, THOMPSON ZJ, GILBERT SM, et al. Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review. Eur Urol, 2025;87(4):427-441.
TEIXEIRA JC, ZEFERINO LC, VALE DB, et al. Transition from opportunistic cytological to organized HPV-based cervical cancer screening in Brazil: results from the first screening round. Sci Rep. 2024;14:22354.
WORLD HEALTH ORGANIZATION. Guide to cancer early diagnosis. Geneva: World Health Organization, 2017.
WORLD HEALTH ORGANIZATION. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2nd ed. Geneva: World Health Organization; 2021.